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Reassurance: Medically Unexplained 
Physical Symptoms 
Bill Anderson
Escobar et al.’s discussion of medically unexplained physical 
symptoms is useful, and could trigger a renewal of how the 
medical profession works [1]. We are in transition at the 
present, and what we have been trained for is less and less 
relevant. This disjunction between our training and practise 
has given rise to a generation of unhappy doctors.
The traditional “doctor” dealt with symptoms and illnesses 
for which there was no useful explanation and became expert 
in managing these. We have completed a century or more 
of science and pathology and have trained doctors to derive 
their interventions from an (often cursory) consideration 
of the patient’s illness and the application of reason within 
this scientiﬁ  c framework, in the unshakable belief that 
this strategy gave the best and at times the only possibility 
of assisting the patient in a meaningful way. The practical 
effects of such practices were rarely if ever examined. This 
approach had many successes but lots of failures, and we have 
moved on. We now have built upon the science a growing 
evidence base which to date principally addresses disease 
states (pathological processes) rather than illnesses (patients’ 
experiences). 
There is however no reason why evidence-based approaches 
cannot be applied to the management of symptoms and 
illness as well as disease states. As we develop that evidence 
base, the nature of clinicians can change. We will not require 
all “doctors,” for want of a better word, to be comprehensively 
trained in bioscience. There will be more need for them to 
deploy skills in implementing well-developed, evidence-based 
interventions and ﬁ  tting them to the illness the patient is 
experiencing. Such “doctors” will deliver most care and pay 
better attention to the patient’s symptoms and illness than 
we do today. We will of course require another different 
sort of “doctor” who will do the research and the sifting to 
develop the evidence base upon which therapies will become 
universally dependent.  
Bill Anderson (bill.anderson@northglasgow.scot.nhs.uk)
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Multidrug-Resistant TB in the 
Philippines: Totem and Taboo
Jose Luis Portero, Maria Rubio
Tupasi et al. [1] show the feasibility and cost-effectiveness 
of treating multidrug-resistant tuberculosis (MDR-TB) in a 
resource-limited setting. These conclusions could lead to 
error since the tertiary hospital where the pilot project was 
carried out is not representative of the average health-care 
setting available for the Filipino tuberculosis patient. 
Resch et al. [2] highlight that this analysis is not an 
independent evaluation and that the intervention was set 
in ideal conditions. In the ﬁ  eld, this pilot project will ﬁ  nd 
serious difﬁ  culties in implementation within the government-
run Filipino National Tuberculosis Program (NTP), where 
the majority of tuberculosis patients are diagnosed and 
treated. Moreover, in recent years Filipino tuberculosis health 
policy has not supported the development of capacities for 
mycobacteria culture and susceptibility tests in the public 
regional laboratories, missing the opportunity to strengthen 
competence on tuberculosis resistance management in 
the whole country. Taking into account the geography (an 
archipelago) and the structure of the NTP, a community-
based pilot project carried out by the governmental 
health centers closer to the patients would have been 
more appropriate to study the feasibility and the real cost-
effectiveness in a resource-limited setting. 
The selection of 118 patients out of 171 eligible may bias 
the ﬁ  nal results increasing the cure rate, since the most 
difﬁ  cult patients to treat, by any circumstance, are also 
more problematic to enroll. A long-term follow-up of the 
patients may modify the ﬁ  nal cure rate. It would have been 
important to analyze if any failure patient developed further 
resistances during the treatment, and the related public 
health implications, as well as a more in-depth discussion 
of the resistance patterns and its relationship with the 
tailored treatment and the ﬁ  nal outcome. Identiﬁ  cation 
of independent variables linked with favorable outcome 
are needed to design future strategies. On the other hand, 
the absence of data about the HIV status of the patients is 
remarkable, considering the ideal conditions of the study and 
the increasing number of cases in the Philippines.
Cost-effectiveness analysis may be holistic and may 
contemplate the MDR-TB control program with the 
rest of the activities of the NTP in order to evaluate 
the convenience and priority of each intervention. 
Unfortunately, the study does not support comprehensible 
strategies to control MDR-TB in the community. Patients, 
families, social activists, and health personnel related to 
tuberculosis control can offer important points of view. A 
larger consensus may avoid the switch of MDR-TB control 
from taboo to totem.  
Jose Luis Portero (jporteronavio@yahoo.com)
Maria Rubio
Madrid, Spain
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Multidrug-Resistant TB in the Philippines: 
Authors’ Reply
The comments of Garner et al. [1] and Portero and Rubio 
[2] on our article, “Feasibility and Cost-Effectiveness of 
Treating Multidrug-Resistant Tuberculosis: A Cohort Study in 
the Philippines” [3] warrant a response. This reply is written 
on behalf of all authors of the original article.
Garner et al. focus on four issues: 1) lack of independence 
because of author afﬁ  liations and ﬁ  nancial support from the 
Global Fund to ﬁ  ght AIDS, TB and Malaria (GFATM); 2) 
whether results can be replicated beyond the pilot project 
that was studied; 3) the need to pay attention to health 
system capacity; and 4) ﬁ  nancial sustainability. Portero and 
Rubio state that Makati Medical Center (MMC) is a tertiary 
institution operating under “ideal” conditions not typical of 
other health facilities, and that lack of attention to building 
laboratory capacity may hinder service expansion. They also 
argue that a community-based care approach should have 
been studied at the pilot stage. 
The standard methods used for statistical analysis and 
economic evaluation in our study [4–6], a rigorous peer-
review process, and the application of previously established 
methods for the evaluation of multidrug-resistant tuberculosis 
(MDR-TB) treatment [7] provide for objectivity in the results 
that are reported. We strongly disagree with the insinuation 
that the participation of the World Health Organization or 
funding from the GFATM biased either the analysis or the 
way in which results were reported.
Pilot projects are often an important ﬁ  rst step in 
implementing and evaluating new interventions. At the same 
time, it is well recognized that results can be different when 
services are scaled up. We agree that care is required when 
interpreting results from pilot projects, and that evaluation 
of MDR-TB treatment when implemented at a larger 
scale is necessary. Our article identiﬁ  es the factors that we 
believe need to be replicated if results are to be reproduced 
elsewhere. In the meantime, it is important to highlight that 
while housed in a tertiary facility, the project was based in 
an outpatient clinic; that the cost-effectiveness results are 
consistent with those for a national programme in Peru [7]; 
and that community-based care is now available. Since 2004, 
patients have been treated at their local public health centre, 
which has helped to increase cure rates and reduce default 
rates compared to those observed during the study period 
[8].
We agree that health system capacity should be considered 
when new interventions are implemented. In the Philippines, 
expansion of MDR-TB treatment has been planned such that 
treatment sites will typically manage one to three patients 
at any given time. Decentralization of services to a larger 
number of treatment sites is helping to integrate MDR-TB 
treatment into existing TB treatment services provided at 
primary health-care level, while increasing accessibility for 
patients. Treatment sites will be overseen by larger treatment 
centres, selected according to various criteria including their 
capacity and willingness to take on additional responsibilities. 
Laboratory and human resource capacity are being enhanced 
at treatment centres and treatment sites, just as capacity 
was enhanced at MMC during the pilot phase. Such costs 
(including infrastructure and training) were included in our 
cost-effectiveness analysis, and Garner et al. are incorrect 
when they state that they were not. All resources used in 
the start-up and implementation phases of the project were 
costed, in line with standard guidelines [4]. 
It is true that most of the current funding for MDR-TB 
treatment is from the GFATM. However, the government 
has provided additional funds for TB control, including 
MDR-TB treatment, since 2005. Funding for the treatment 
of new drug-susceptible cases has not been reduced. This 
demonstrates that MDR-TB treatment can be provided 
without compromising basic tuberculosis control. Indeed, 
some of the investments needed for expansion of MDR-
TB treatment, such as building laboratory capacity, may 
strengthen the health system as a whole. 
Regarding more speciﬁ  c criticisms [2], the lack of HIV 
testing and long-term follow-up are acknowledged in our 
article (though HIV prevalence remains low, at less than 
0.1%) [9]. We speciﬁ  cally compared patients who were 
enrolled with patients who were eligible but not enrolled. 
The two groups were similar, except that enrolled cases had 
more, rather than less, severe patterns of drug resistance. 
Results are referred to in our article and reported in 
supplementary material.  As reported in our article, we 
analyzed the relationship between several variables and 
treatment outcomes; the only statistically signiﬁ  cant result was 
that women appeared more likely to be cured than men. Also, 
contrary to the claim made by Portero and Rubio, Resch et 
al. made no suggestion that our study lacked independence 
[10].
In conclusion, the overall goal of our study was to 
contribute to the evidence base on the management of 
MDR-TB in low- and middle-income countries. We support 
the development and implementation of evidence-based 
management strategies for all TB patients.  
Thelma Tupasi (tetupasi@yahoo.com)
Tropical Disease Foundation
Makati City, Philippines
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HIV-1 Viral Load Assays for Resource-
Limited Settings: Clades Matter 
Wolfgang Preiser, Jan Felix Drexler, Christian Drosten
The paper by Fiscus et al. [1] gives an excellent overview 
of current technologies to measure HIV-1 viral load (VL), 
and highlights the problems with ﬁ  nding assays that, whilst 
affordable and practicable, provide reliable and high-quality 
results to guide patient management in resource-constrained 
settings.
One concern, which in our mind does not receive enough 
attention in the paper, is HIV variability. The assays’ ability 
to reliably quantitate non-B HIV-1 subtypes and strains is of 
paramount importance, given the predominance of non-B 
HIV infections in developing countries [2]. Unfortunately, 
genotype bias has not been assessed systematically for most of 
the assays described in the paper.
In our recent paper, “Ultrasensitive Monitoring of HIV-1 
Viral Load by a Low-Cost Real-Time Reverse Transcription-
PCR Assay with Internal Control for the 5’ Long Terminal 
Repeat Domain” [3] (which is found by Fiscus et al.’s PubMed 
search strategy for “HIV-1 viral load AND resource-limited 
settings” but presumably just missed the deadline for [1]), we 
describe an inexpensive assay targeting the conserved long 
terminal repeat (LTR) domain of HIV-1.
In addition to comparing the assay with three commercial 
tests using patient samples from Brazil, South Africa, India, 
and Germany, we also extensively determined its ability to 
accurately quantitate different HIV-1 subtypes. For this we 
used two HIV-1 subtype reference panels (National Institute 
for Biological Standards and Control: HIV-1 M subtypes A, 
B, C, D, circulating recombinant form [CRF] AE, F, G, H, 
and HIV-1 N and O; German National Reference Centre for 
Retroviruses: HIV-1 M subtypes A, B, C, D [2 samples], CRF 
AE, F, G, and HIV-1 O [2 samples]), as well as 12 plasma 
samples from patients infected with non-B subtypes, including 
genotypes not present in the reference panels, e.g., CRFs AE 
and AG and subtype J, as determined by sequence analysis.
We demonstrated that LTR is highly suitable for the 
quantiﬁ  cation of “exotic” HIV-1 genotypes: For all genotypes, 
except for groups N and O, the overall results of virus 
quantiﬁ  cation using different assays were highly concordant. 
For HIV-1 M clades and CRFs, the differences between 
our assay and the Roche Monitor assay were below 0.5 log; 
this excellent comparability between the assays is clinically 
acceptable. The reduced risk of genotype bias makes 
monitoring of HIV-1 VL feasible, to improve individual 
patient management as well as hopefully delay the emergence 
and spread of antiretroviral drug resistance.
Our test is at least as good as commercial tests with regard 
to performance and technical features: The internal control 
allows recognition of inhibition and thus falsely low or 
negative results; its accuracy at least equals that of commercial 
assays; its analytical sensitivity (down to 32 copies/ml 
according to industry-agreed evaluation procedures including 
probit analysis) and broad quantiﬁ  cation range are sufﬁ  cient 
for both treated and untreated patients; and it is much 
cheaper than comparable commercial assays—less than 
US$10 for reagents per sample and below US$20, including 
the service licence payable to Roche. Its only disadvantage is 
that it still requires relatively expensive equipment, a certain 
infrastructure, and skilled personnel. Large-scale feasibility 
studies have commenced in Brazil, and Stellenbosch 
University in South Africa is going to set up the assay for viral 
load testing.
Given the large and sadly still rapidly increasing 
populations of HIV-1-infected individuals in many resource-
constrained countries, together with the drive to provide 
universal access to antiretroviral treatment and the looming 
danger of antiretroviral drug resistance as a signiﬁ  cant public 
health problem jeopardising the success of antiretroviral 
treatment programmes [4,5], the potential beneﬁ  t of 
affordable HIV-1 VL assays is enormous. The challenge lies 
in ensuring that these assays are adequate for the respective 
situation, particularly with regard to HIV-1 strain diversity.  
Wolfgang Preiser (preiser@sun.ac.za)
Faculty of Health Sciences, Stellenbosch University
National Health Laboratory Service 
Tygerberg, South Africa
Jan Felix Drexler
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Bernhard Nocht Institute for Tropical Medicine
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HIV-1 Viral Load Assays for Resource-Limited Settings: 
Authors’ Reply
We thank Drs. Preiser, Drexler, and Drosten for their letter 
[1] and share their concerns regarding HIV-1 viral load assays 
in resource-limited settings. The real-time RT-PCR (reverse-
transcriptase polymerase chain reaction) assay they have 
developed had not yet been published when our review was 
submitted or revised. As noted in Table 1 of our review, many 
of the current viral load assays require additional evaluation 
with different subtypes and others may underestimate non-B 
subtypes. In addition, under the heading “What is needed 
for implementation of simpliﬁ  ed viral load testing?” we state 
“First, each country must determine if the assay will quantify 
subtypes common in the region and is appropriate for the 
technical staff and laboratory equipment available.”
In-house assays require production, optimization, 
validation, and quality assurance of all reagents, which is 
challenging in any circumstances, and would be extremely 
difﬁ  cult in laboratories in most resource-limited settings. 
Real-time PCR instruments are expensive and maintenance 
in many places would be a problem. What is really needed is a 
technologically much simpler, much less expensive, perhaps 
semi-quantitative assay for measuring viral load.  
Susan A. Fiscus (ﬁ  scussa@med.unc.edu)
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States of America
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Enrolling Adolescents in Research on 
HIV: Young Women Must Be Included 
Alana de Kock, Stephanie Skoler, Khatija Ahmed, 
Sumen Govender
As researchers managing an HIV prevention microbicide 
trial, which takes place across three provinces, we would 
like to commend Singh et al. for their informative article on 
the need to include adolescent women in HIV prevention 
trials [1]. This commendation is based on our clinical trial 
experience where we have enrolled 16- and 17-year-old 
women and are actively continuing with their follow-up.
In our study, we include these young women, who are often 
those at highest risk for HIV infection, for several reasons. 
Most notable among these are:
(1) All participants in HIV prevention trials (regardless 
of the arm to which they are randomised) have a reduced 
risk of HIV infection, due to the intervention of preventive 
counselling and education that is ethically required for 
participants in such trials. In addition, access to sexually 
transmitted infection (STI) diagnosis and treatment and 
referrals for partner treatment while in the clinical trial 
further serves to reduce risk factors for HIV infection and STI 
re-infection.
(2) These young women are sexually active and at risk, 
and form part of the end-user constituency for a proven 
microbicide. This sexual activity is evidenced by statistics from 
the Human Sciences Research Council for 2005 for South 
Africa, which show that the prevalence of HIV in the 15- to 
34-year-old group is 20%. Furthermore, the Children’s Bill 
passed in June 2005 [2] says that young women can have 
access to contraception from the age of 12 years without 
parental consent. It is thus ethically imperative that young 
women should be included in the testing of such products.
(3) Including those currently at greatest risk for infection 
ensures that the study will be able to detect the efﬁ  cacy of the 
intervention. 
It is clear that both the participants and the research 
question beneﬁ  t from the inclusion of younger women 
in communities where HIV risk is high and education, 
counselling, and new prevention technologies are needed.
Younger women are most at risk when it comes to 
sexual transmission of HIV [3]. Clinical HIV prevention 
trials provide an environment where conﬁ  dentiality can 
be maintained and where young women can be educated 
on methods to protect themselves in a conﬁ  dential and 
consistent manner through trial participation. Thus, the 
inclusion of young women in such trials is an opportunity 
to empower the younger generation of young women 
across communities. To deny that these young women are 
sexually active would be to turn a blind eye to an important 
epicentre of the epidemic, and counterproductive to the HIV 
prevention research agenda.
The age of consent for adolescent participation in clinical 
trials without obtaining legal guardian/parental support 
is a major factor that complicates their involvement in 
HIV prevention trials and other health-care research. The 
requirement for parental consent that often accompanies 
the ethical approval process of most studies is at times an 
insurmountable barrier and distances the young women that 
require this type of intervention from securing access to these 
potential prevention options. As Singh et al. point out, there 
are many salient reasons why adolescents can and should 
be considered capable of giving informed consent without 
parental assent or approval. 
Researchers must continue to work in collaboration with 
local and scientiﬁ  c communities, ethics committees, and 
policy makers to ensure that the need for the participation of 
young women in HIV prevention trials is understood. It would 
seem then that both researchers and ethicists should work 
with actual examples of ethical research activities that include 
adolescents without parental involvement, in order to develop 
guidelines for adolescent research in the ﬁ  eld of HIV that are 
both protective and practical.  
Alan de Kock (dekock@cormack.uct.ac.za)
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HIV-1 Subtype and Reverse 
Transcriptase Genotype: Role for 
Geographical Location and Founder 
Effects
Akinyemi I. Ojesina, Phyllis J. Kanki
In a previous issue of PLoS Medicine, Kantor et al. [1] 
published very impressive results from an international 
multicenter collaboration in which they reported signiﬁ  cant 
overlap between subtype B drug resistance mutations and 
mutations associated with at least one non-B isolate in HIV-1 
reverse transcriptase (RT) and protease. This information 
is very useful for planning large-scale global surveys for 
antiretroviral drug resistance.
The authors described subtype-speciﬁ  c polymorphisms as 
mutations that were signiﬁ  cantly more prevalent in each non-
B subtype than in subtype B viruses from untreated persons. 
Amongst these was an A98S mutation in HIV-1 reverse 
transcriptase, which was described as a subtype G–speciﬁ  c 
polymorphism.
In Nigeria, the predominant variants of HIV-1 are the 
circulating recombinant form CRF02_AG and subtype G. 
The 98S polymorphism was not found in 35 of 35 sequences 
obtained from a group of HIV-1-infected drug-naïve 
Nigerians, and the consensus at this position was A98 [2].
Kantor et al. [1; Table 1 and Figure 4] describe how 207 
out of 294 (70%) of the subtype G samples were obtained 
from Portugal and Spain, while approximately half of the 
subtype G samples had polymorphisms (with respect to 
subtype B consensus) at RT position 98. We hypothesized 
that a signiﬁ  cant correlation exists between the samples 
from Portugal and Spain and the presence of the A98S 
polymorphism in HIV-1 reverse transcriptase reported by 
the authors. It is however possible that this polymorphism 
is similarly prevalent in subtype G sequences from other 
countries. 
We therefore interrogated the Stanford HIV Drug 
Resistance Database [3], where the updated results from 
this international collaboration maintain detailed RT 
mutation data for subtype G isolates. The output has detailed 
information on GenBank accession numbers and publication 
data, from which we deduced the country of sampling. In 
all, amino acid residue information for RT position 98 was 
available for 500 subtype G isolates from both drug-naïve 
and treated persons: 351 isolates (70%) with the A98S 
polymorphism, 143 isolates (29%) with the wild type A98A 
residue, and six isolates (1%) with the A98G mutation. 
In order to determine if A98S is a subtype G-speciﬁ  c 
polymorphism, only the 165 isolates obtained from drug-
naïve persons with either A98S or A98A were used in this 
analysis. 57 (34.5%) of these selected isolates were from 
Portugal and Spain. 51 (89.5%) of the isolates from Portugal 
and Spain had the A98S polymorphism, compared with 
only 10 (9.3%) of the 108 isolates from other countries 
combined. Therefore, a very strong association exists between 
the presence of the A98S polymorphism and sampling from 
Portugal and Spain (p is less than 0.0001). This suggests that 
the A98S polymorphism in HIV-1 subtype G is not subtype-
speciﬁ  c, but may be the consensus amino acid residue for 
samples from Portugal and Spain. Indeed, this polymorphism 
has been previously reported as being unique to samples from 
these countries [4]. 
Considering that various HIV-1 variants have geographical 
bias [5], it is possible that patterns of subtype-speciﬁ  c 
polymorphisms may be differentially predominant in certain 
geographical locations with respect to others. The presence 
of speciﬁ  c mutations in drug-naïve individuals may inﬂ  uence 
decisions on the choice of therapeutic regimens [6]. 
Therefore, the description of subtype-speciﬁ  c polymorphisms 
without stratifying by geographical location, or controlling 
for the role of closely related founder viruses, may result in 
misleading generalizations. Examination of the role of the 
source of samples in multicenter studies may be pertinent 
in assigning the tag of subtype-speciﬁ  c polymorphisms, 
especially for HIV-1 variants with signiﬁ  cant transcontinental 
distribution, for example, HIV-1 subtypes C and G.  
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Cost-Effective Control of Drug-
Resistant TB: Listening to Other Voices
Jose Luis Portero, Maria Rubio
Drug-resistant tuberculosis is mainly a phenomenon caused 
by physicians, patients, and health-care systems through 
incorrect treatments, noncompliance, and poor delivery of 
tuberculosis services, respectively. These man-made facts 
could be avoided with appropriate actions. However, the 
weakness of health systems in the tuberculosis high-burden 
countries hampers successful control. 
Public health priorities in resource-poor settings have 
marginalized tuberculosis cases resistant to ﬁ  rst-line 
treatment. Nevertheless, patients have been claiming their 
rights to be treated despite their drug resistance pattern. 
Nowadays, tuberculosis programs try to address drug 
resistance issues. However, pilot experiences in low-resource 
settings do not fully answer to the real challenges in the ﬁ  eld 
to scale up second-line drug treatments [1].
Governments from high-burden countries must enhance 
their commitments with their respective communities to 
provide better health and to alleviate poverty. Regarding 
drug-resistant tuberculosis control, these actions would 
improve organization and effectiveness in all levels of 
the tuberculosis programs to avoid misuse of resources. 
In addition, it is a must to address ignorance about 
tuberculosis transmission and treatment, social stigma, 
and discrimination. However, the current program design 
to control drug-resistant tuberculosis underestimates the 
environment of poverty suffered by the patients. In this sense, 
it is paradigmatic that one of the obstacles to following the 
treatment in the last pilot project published was that the 
patients were unable to buy symptomatic drugs to relieve the 
second-line drug side effects [2]. Governments, the World 
Health Organization, physicians, and technocrats must open 
their eyes to the reality in the ﬁ  eld [3].
Unfortunately, we are far worldwide from a reliable system 
to ﬁ  ght drug-resistant tuberculosis. The complexity and 
requirements of treating resistant cases generally exceed the 
average available health care. In the other hand, the current 
cost of second-line anti-tuberculosis drugs is unbearable for 
the developing world and is a great obstacle to the scaling-up 
of the treatment. The cost of the drugs and the laboratory 
supplies is not appropriate for developing countries. 
No signiﬁ  cant steps have been taken to put in practice 
a coordinated system to manage drug resistance in the 
community. Cost-effectiveness studies do not usually reﬂ  ect 
the hidden costs for the patients and the real cost of the 
interventions in the present conditions. Feasibility measures 
do not take into account most of the socioeconomic barriers 
in the ﬁ  eld.
There is a lack of independent opinions regarding drug-
resistant tuberculosis, so the article by Resch et al. is very 
valuable [4]. Tuberculosis experts are in danger of listening 
only to their own words enclosed in a technocrat circle. It 
would be desirable to open tuberculosis control to civil society 
and to listen to other voices.  
Jose Luis Portero (jporteronavio@yahoo.com)
Maria Rubio
Madrid, Spain
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